These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19328538)

  • 1. PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.
    Kaplan SA; Roehrborn CG; Meehan AG; Liu KS; Carides AD; Binkowitz BS; Heyden NL; Vaughan ED
    Urology; 2009 May; 73(5):935-9. PubMed ID: 19328538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
    Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
    J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of prostate cancer with finasteride: US/European perspective.
    Thompson IM; Klein EA; Lippman SM; Coltman CA; Djavan B
    Eur Urol; 2003 Dec; 44(6):650-5. PubMed ID: 14644115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study.
    Liang Y; Ketchum NS; Louden C; Jimenez-Rios MA; Thompson IM; Camarena-Reynoso HR
    Urol Int; 2012; 89(1):9-16. PubMed ID: 22626812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.
    Lucia MS; Darke AK; Goodman PJ; La Rosa FG; Parnes HL; Ford LG; Coltman CA; Thompson IM
    Cancer Prev Res (Phila); 2008 Aug; 1(3):167-73. PubMed ID: 19138952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
    Lucia MS; Epstein JI; Goodman PJ; Darke AK; Reuter VE; Civantos F; Tangen CM; Parnes HL; Lippman SM; La Rosa FG; Kattan MW; Crawford ED; Ford LG; Coltman CA; Thompson IM
    J Natl Cancer Inst; 2007 Sep; 99(18):1375-83. PubMed ID: 17848673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-alpha-reductase Inhibitors for prostate cancer prevention.
    Wilt TJ; MacDonald R; Hagerty K; Schellhammer P; Kramer BS
    Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD007091. PubMed ID: 18425978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
    Thompson IM; Tangen CM; Goodman PJ; Lucia MS; Parnes HL; Lippman SM; Coltman CA
    J Urol; 2007 May; 177(5):1749-52. PubMed ID: 17437804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.
    Fowke JH; Howard L; Andriole GL; Freedland SJ
    Eur Urol; 2014 Dec; 66(6):1133-8. PubMed ID: 24568894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.
    Ankerst DP; Till C; Boeck A; Goodman P; Tangen CM; Feng Z; Partin AW; Chan DW; Sokoll L; Kagan J; Wei JT; Thompson IM
    J Urol; 2013 Jul; 190(1):70-6. PubMed ID: 23313212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
    Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
    Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of finasteride on the development of prostate cancer.
    Thompson IM; Goodman PJ; Tangen CM; Lucia MS; Miller GJ; Ford LG; Lieber MM; Cespedes RD; Atkins JN; Lippman SM; Carlin SM; Ryan A; Szczepanek CM; Crowley JJ; Coltman CA
    N Engl J Med; 2003 Jul; 349(3):215-24. PubMed ID: 12824459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial.
    Hernandez J; Gelfond J; Goros M; Liss MA; Liang Y; Ankerst D; Thompson IM; Leach RJ
    PLoS One; 2018; 13(10):e0204823. PubMed ID: 30300367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.
    Kim J; Davis JW; Klein EA; Magi-Galluzzi C; Lotan Y; Ward JF; Pisters LL; Basler JW; Pettaway CA; Stephenson A; Li Ning Tapia EM; Efstathiou E; Wang X; Do KA; Lee JJ; Gorlov IP; Vornik LA; Hoque AM; Prokhorova IN; Parnes HL; Lippman SM; Thompson IM; Brown PH; Logothetis CJ; Troncoso P
    EBioMedicine; 2016 May; 7():85-93. PubMed ID: 27322462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
    Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
    Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
    Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
    Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
    BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
    Andriole G; Bostwick D; Civantos F; Epstein J; Lucia MS; McConnell J; Roehrborn CG
    J Urol; 2005 Dec; 174(6):2098-104. PubMed ID: 16280736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.
    Ankerst DP; Hoefler J; Bock S; Goodman PJ; Vickers A; Hernandez J; Sokoll LJ; Sanda MG; Wei JT; Leach RJ; Thompson IM
    Urology; 2014 Jun; 83(6):1362-7. PubMed ID: 24862395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.